4.4 Article

Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens

Journal

JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
Volume 28, Issue 6, Pages 804-810

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jvir.2017.01.018

Keywords

-

Funding

  1. University of Reims Champagne-Ardenne
  2. Unite Mixte de Recherche/Centre National de la Recherche Scientifique Matrice Extracellulaire et Dynamique Cellulaire [7369]

Ask authors/readers for more resources

This study evaluated the midterm delivery of doxorubicin in liver specimens from patients (N = 4) with hepatocellular carcinoma treated with drug-eluting embolic (DEE) transarterial chemoembolization. The patients had surgical resection 57, 79, 80 and 105 days after doxorubicin DEE chemoembolization. Doxorubicin concentrations inside embolic particles and in surrounding tissues were assessed by infrared microspectroscopy and microspectrofluorimetry, respectively. Embolic particles still contained doxorubicin and provided sustained drug delivery Within targeted tissues 80 days after chemoermbolization. Doxorubicin was undetectable after 105 days. In addition, aggregation of embolic particles inside vessel lumina was associated with slower doxorubicin elution and higher tissue concentrations when the number of aggregated embolic partides increased.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available